Clinical trials: Coronavirus Infection
COVID-19
The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine
To fast respond the coronavirus disease of 2019 (COVID-19) pandemic, the Indonesian government has launched "Vaksinasi Gotong Royong" (a mutual cooperation vaccination program) in which any company/legal entity/business entity…
- Trial name
- NCT05126550
- Testing
- SARS-CoV-2 vaccine (Vero cell) inactivated
- Where
- 4 sites in Indonesia
- Volunteers
- 435 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
COVID-19
Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine
This Phase 3 study is intended to assess clinical lot-to-lot consistency by evaluating and comparing the immunogenicity of three consecutively manufactured lots of Coronavirus-like Particle (CoVLP).
- Trial name
- NCT05040789
- Testing
- CoVLP formulation
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medicago
Covid19, Cytokine Release Syndrome
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
The purpose of this study is to assess the safety and efficacy of orally administered NLRP3 inhibitor, dapansutrile, for the treatment of moderate COVID-19 symptoms and early cytokine release syndrome (CRS) in patients with…
- Trial name
- NCT04540120
- Testing
- dapansutrile capsules
- Where
- 10 sites in United States, Switzerland
- Volunteers
- 49 people
- Sponsor
- Olatec Therapeutics, Inc.
Covid19, Corona Virus Infection
A Study of Baricitinib (LY3009104) in Children With COVID-19
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
- Trial name
- COV-BARRIER (NCT05074420)
- Testing
- Baricitinib
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Covid19
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19
This is a randomized, placebo-controlled study to assess the safety, PK profile, and efficacy of COVI-AMG in subjects with COVID-19.
- Trial name
- NCT04584697
- Testing
- COVI-AMG
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
The purpose of this study is to learn about: effects of living with COVID-19 and how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan.
- Trial name
- NCT06085924
- Testing
- SoC, Disease description
- Where
- Taiwan
- Volunteers
- 2,315,187 people
- Sponsor
- Pfizer
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
Background - A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness COVID-19 in Wuhan City, China.
- Trial name
- NCT04596839
- Testing
- Remdesivir, Standard of Care
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Dr. Md. Alimur Reza
COVID-19, SARS-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥18 years and previously fully immunized with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with…
- Trial name
- NCT05238454
- Testing
- SCTV01C, Sinopharm inactivated COVID-19 vaccine, Comirnaty
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19
This is a Phase 2, randomized, double-blind, multicentre, placebo-controlled study in adults to assess the safety and efficacy of inhaled IBIO123, for post-exposure prophylaxis of COVID-19.
- Trial name
- NCT05639166
- Testing
- IBIO123
- Where
- 5 sites in South Africa, Ukraine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Immune Biosolutions Inc
COVID-19 (Coronavirus Disease 2019)
The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants
This is double-blind,randomized, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety, tolerability and drug-drug interaction of RAY1216, and the effect of food on RAY1216 Pharmacokinetics.
- Trial name
- NCT05829551
- Testing
- RAY1216 dose 1, RAY1216 dose 2, RAY1216 dose 3
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
SARS-CoV-2
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
- Trial name
- NCT04958954
- Where
- United States
- Volunteers
- 50,000,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers
This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults with COVID-19
- Trial name
- NCT04576312
- Testing
- UNI911 inhalation 1% and intranasal spray 1%
- Where
- Denmark
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- UNION therapeutics
COVID-19 Virus Infection
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged…
- Trial name
- NCT04560881
- Testing
- Inactivated SARS-CoV-2 vaccine (Vero cell)
- Where
- 4 sites in Argentina
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
COVID-19 Pandemic
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5
It is a single center, randomized, open-labeled, exploratory clinical study to evaluate the safety and immunogenicity of Recombinant SARS-CoV-2 Fusion Protein bivalent Vaccine V-01-B5 as a second booster in adults aged 18-59…
- Trial name
- COVID-19 (NCT05585567)
- Testing
- V-01/V-01-B5, V-01-351/V-01-B5, V-01
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19, Pneumonia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in…
- Trial name
- NCT04500067
- Testing
- IVIG
- Where
- 9 sites in Ukraine
- Volunteers
- 76 people
- Sponsor
- Biopharma Plasma LLC
SARS-CoV-2 Infection (Asymptomatic), SARS-CoV-2 Infection (Symptomatic)
COVID-19 Progression in End-Stage Kidney Disease
The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
- Trial name
- COPE (NCT04495907)
- Where
- 11 sites in United States
- Volunteers
- 412 people
- Sponsor
- Davita Clinical Research
Covid19
COVID-19 International Drug Pregnancy Registry
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild…
- Trial name
- COVID-PR (NCT05013632)
- Testing
- Antiviral Agents, Monoclonal antibody
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Pregistry
Patients With Moderate or Severe COVID-19
Efficacy of Amantadine Treatment in COVID-19 Patients
Demonstration of the efficacy of amantadine over placebo in the population of patients with moderate or severe COVID-19 in the initial stage of the disease treated in the hospital
- Trial name
- TITAN (NCT04952519)
- Testing
- Amantadine
- Where
- 12 sites in Poland
- Volunteers
- 193 people
- Sponsor
- Noblewell
Post-acute COVID-19 Syndrome
SENSING-AI in Patients With Long COVID (SENSING-AI)
The retrospective study will be used to develop an artificial intelligence model of risk stratification of physiological and psychological complications arising from the information available in the electronic medical record and…
- Trial name
- SENSING-AI (NCT06247332)
- Testing
- Review of available clinical data sources related to use cases
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Adhera Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.